Viewing Study NCT05432193

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:17 AM
Ignite Modification Date: 2026-02-23 @ 5:44 AM
Study NCT ID: NCT05432193
Status: TERMINATED
Last Update Posted: 2025-06-25
First Post: 2022-06-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pancreatic Ductal Adenocarcinoma View
None Colorectal Cancer View
None Esophageal Cancer View
None Melanoma (Skin) View
None Soft Tissue Sarcoma View
None Head and Neck Squamous Cell Carcinoma View
None Cholangiocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None radioligand therapy View
None FRONTIER View
None PNT6555 View
None 177Lu-FAP View
None 68Ga-FAP View
None PDAC View
None CRC View
None Melanoma View
None STS View
None Esophageal cancer View
None fibroblast activation protein View
None FAP View
None FAPi View
None Lu-177 View
None GA-68 View
None HNSCC View
None Cholangiocarcinoma View